AEON AEON Biopharma, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1837607 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,587,233.3%
TTM EPS YoY-222.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-416.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets83.1%
Debt / equity0.00x
Current ratio2.75x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-269.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.51M | $2.94M | $2.03M | $1.61M | $597,000 | $1.06M | $825,000 | $3.04M |
| SG&A expense | $2.99M | $2.99M | $3.90M | $3.89M | $1.93M | $3.26M | $3.12M | $2.63M |
| Operating income | -$4.48M | -$5.92M | -$5.93M | -$5.51M | -$2.49M | -$4.34M | -$462,000 | -$2.32M |
| Pretax income | $2.46M | -$1.16M | -$11.79M | -$37.14M | -$4.54M | -$6.64M | $9.10M | $2.08M |
| Net income | $2.46M | -$1.16M | -$11.79M | -$37.14M | -$4.54M | -$6.64M | $9.10M | $2.08M |
| EBITDA | -$4.47M | -$5.90M | -$5.91M | -$5.49M | -$2.47M | -$4.32M | -$443,000 | -$2.30M |
| EPS (basic) | 0.01 | -0.02 | -0.29 | — | -0.39 | -0.60 | 2.28 | — |
| EPS (diluted) | 0.01 | -0.02 | -0.29 | — | -0.39 | -0.60 | 2.28 | — |
| Weighted avg. shares (diluted) | 89.96M | 50.53M | 40.61M | — | 11.63M | 11.09M | 3.98M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $11.42M | $3.43M | $6.24M | $3.01M | $5.93M | $8.44M | $10.45M | $13,000 |
| Current assets | $12.56M | $3.99M | $6.62M | $3.40M | $7.41M | $10.26M | $12.32M | $1.59M |
| PP&E, net | $58,000 | $123,000 | $142,000 | $162,000 | $181,000 | $200,000 | $220,000 | $235,000 |
| Total assets | $14.13M | $5.91M | $8.63M | $5.56M | $8.73M | $11.66M | $13.80M | $3.14M |
| Current liabilities | $4.57M | $7.34M | $6.67M | $6.90M | $8.23M | $9.13M | $8.64M | $14.15M |
| Total liabilities | $11.74M | $21.27M | $25.38M | $60.59M | $28.61M | $27.51M | $25.12M | $31.71M |
| Shareholders' equity | $2.39M | -$15.36M | -$16.75M | -$55.03M | -$19.87M | -$15.85M | -$11.32M | -$28.57M |
| Shares outstanding | 59.08M | 26.31M | 25.30M | 12.11M | 11.64M | 11.54M | 10.54M | 555,511 |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.72M | -$3.70M | -$2.64M | -$4.71M | -$2.60M | -$2.09M | -$7.91M | -$621,000 |
| Capital expenditure | — | — | — | $0 | $0 | $0 | $4,000 | — |
| Free cash flow | — | — | — | -$4.71M | -$2.60M | -$2.09M | -$7.91M | — |
| Investing cash flow | — | — | — | $0 | $0 | $0 | -$4,000 | — |
| Financing cash flow | $13.72M | $886,000 | $5.87M | $1.79M | $84,000 | $84,000 | $18.35M | $97,000 |
| Depreciation & amortization | $15,000 | $20,000 | $19,000 | $20,000 | $19,000 | $20,000 | $19,000 | $23,000 |
| Stock-based compensation | $1.60M | $1.90M | $1.93M | $1.59M | $1.00M | $1.70M | $1.73M | $1.34M |
Free plan shows the latest 8 periods; Pro shows all 22 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.